APA (7th ed.) Citation

Wing Lam, Mohammad Arammash, Wei Cai, Wei Cai, Fulan Guan, Zaoli Jiang, . . . Yung-Chi Cheng. (2023). YIV-818-A: A novel therapeutic agent in prostate cancer management through androgen receptor downregulation, glucocorticoid receptor inhibition, epigenetic regulation, and enhancement of apalutamide, darolutamide, and enzalutamide efficacy. Frontiers Media S.A..

Chicago Style (17th ed.) Citation

Wing Lam, Mohammad Arammash, Wei Cai, Wei Cai, Fulan Guan, Zaoli Jiang, Shwu-Huey Liu, Peikwen Cheng, and Yung-Chi Cheng. YIV-818-A: A Novel Therapeutic Agent in Prostate Cancer Management Through Androgen Receptor Downregulation, Glucocorticoid Receptor Inhibition, Epigenetic Regulation, and Enhancement of Apalutamide, Darolutamide, and Enzalutamide Efficacy. Frontiers Media S.A., 2023.

MLA (9th ed.) Citation

Wing Lam, et al. YIV-818-A: A Novel Therapeutic Agent in Prostate Cancer Management Through Androgen Receptor Downregulation, Glucocorticoid Receptor Inhibition, Epigenetic Regulation, and Enhancement of Apalutamide, Darolutamide, and Enzalutamide Efficacy. Frontiers Media S.A., 2023.